Pharma Pulse 11/7/24: The Future of Financing Innovation, Homeless Doesn't Have To Mean Health Plan-Less & more

Dealmaking and Partnerships: The Future of Financing Innovation

At the Financial Times’ Global Pharma and Biotech Summit 2024, a breakout panel discussed how dealmaking remains vital for biopharma companies facing pipeline and revenue pressures.

Homeless Does Not Have To Mean Health Plan-Less

Two of Los Angeles’ largest health insurers will invest $90 million over the next five years to improve health care and access to social services and housing for Los Angeles County’s homeless population.

Election Wargames: Tech and Politics Try Their Hands at Detecting Voting Threats

‘Risk games’ hosted by Lux Capital expose the difficulty of identifying technology-related election threats.

Cancer Antibody Drug Conjugates Market, Drugs Approval, Price, Sales & Clinical Trials Insight to 2030

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com offering.

The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.

Kimberly Lyons on LinkedIn

How are pharma supply chains adapting to new regulations and industry trends? Kenco’s VP of Life Sciences, Tim McClatchy, outlines three key challenges in Pharmaceutical Commerce Magazine. Dive into the details here!

#lifesciences #PharmaceuticalCommerce #supplychain #3pl #Kenco

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs